spacer
home > ebr > winter 2009 > optimising the supply chain
PUBLICATIONS
European Biopharmaceutical Review

Optimising the Supply Chain

Faced with thinning drug pipelines, increased competition from generics and declining sales, pharmaceutical companies have spent much of the last decade engaged in a kind of stimulus-response exercise, slashing their sales workforces and cutting administrative budgets to levels that were commensurate with demand.

But increasingly, the industry’s leading executives are realising that these moves not only oversimplify the problem, but cost savings are often short-lived and the same challenges remain. The evolution in strategic planning for these executives is now shifting the focus to more sustainable efficiency gains, the like of which can only be obtained by reassessing cost structures across the entirety of the enterprise.

Amid this transition, the supply chain is attracting unprecedented focus. As the global reach of large integrated pharmaceuticals widens, supply chain management is becoming just as important as tax has been for the industry for years.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Mark B Hassenplug is a principal in Ernst & Young’s Business Advisory Services practice, and is the Global Pharmaceutical Markets Leader. He has more than 23 years of management consulting and business advisory services experience in the areas of strategic planning, business transformation, supply chain and manufacturing operations, customer relationship management, shared services design and implementation and enterprise resource planning systems implementations. Having conducted engagements for clients in the US, Europe, Africa, Middle East and Asia he has a unique perspective on the global issues that face multinational pharmaceutical corporations.

Kai Gindner is the Leader of the Supply Chain Management Practice in Switzerland at Ernst & Young. He joined the firm in July 2007 after over 10 years in consultancy services at KPMG, BearingPoint and smaller boutique firms. Kai is experienced in leading complex international supply chain strategy and process and transformation programs. He is a speaker at conferences and seminars and publishes articles on supply chain management in the consumer products and life sciences industries. Kai has a Masters of Business Administration from Mannheim University.

spacer
Mark B Hassenplug
spacer
spacer
spacer
Kai Gindner
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT Acquires Cypex, a Leading Manufacturer of Drug-Metabolizing Enzymes

Westbury, NY – August 8, 2022 – BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that it has acquired Cypex, a renowned manufacturer of recombinant xenobiotic metabolizing enzymes, based in Dundee, Scotland. Cypex’s extensive enzyme portfolio covers a wide range of proteins involved in drug metabolism.
More info >>

White Papers

Accelerating the Time from DNA to Material

Merck

Cell line development is a critical step in upstream process development for monoclonal antibodies (mAbs). Unfortunately, the search for the bestproducing clone can be labor- and resource-intensive and is often compared with looking for a needle in a haystack. Cells must first be engineered to produce the biologic of interest and the cell line generated from a high producing clone must deliver a sufficiently high titer to support clinical studies, and ultimately commercialization of the therapeutic.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement